A Phase 2, Randomized, Double Blind, Controlled Study to Evaluate the Safety of VX-152 Combination Therapy in Adults With Cystic Fibrosis
Phase of Trial: Phase II
Latest Information Update: 18 Jul 2017
At a glance
- Drugs Ivacaftor (Primary) ; Tezacaftor (Primary) ; VX 152 (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions; Proof of concept
- Sponsors Vertex Pharmaceuticals
- 18 Jul 2017 Results published in the Vertex Pharmaceuticals media release.
- 08 Jan 2017 According to a Vertex Pharmaceuticals media release, the first data from this trial are expected in the second half of 2017.
- 30 Nov 2016 Status changed from not yet recruiting to recruiting.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History